Treatment for hepatitis C is associated with a reduction in cardiovascular events.
All articles by Roxanne Nelson, BSN, RN
CAP guidelines recommend transitioning to an oral beta-lactam or fluoroquinolone regimen when patients are clinically stable, but because of common adverse effects, stewardship efforts are frequently focused on reducing initial fluoroquinolone use for CAP therapy.
Publish Date
-
Latest News Your top articles for Thursday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses